Montana

• An Open-Label Extension to Study the Long-Term Effect of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) Under evaluation
  2024-510810-33-00 5 2024-10-14 Severe eosinophilic asthma
• Efepoetin alfa for treatment of anemia in chronic kidney disease on dialysis Not authorised
  2023-503634-50-00 5 Anemia in patients with chronic kidney disease on dialysis
• A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of IM-101 in Adult Participants with Generalized Myasthenia Gr … Pending
  2025-522406-20-00 9 Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
• A study to test if tenecteplase helps people to recover from an acute stroke when given more than 4.5 hours after the person was last seen w … Pending
  2025-522542-40-00 5 Acute Ischemic Stroke
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending
  2025-523510-87-00 5 Obesity
• Efficacy and Safety of KAI-9531 compared with Semaglutide in Participants Living With Obesity Who Do Not Have Diabetes Pending
  2025-523511-11-00 5 Obesity
• Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla … Recruiting
  2023-507746-83-00 5 2024-11-27 Generalized Myasthenia Gravis
• Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting
  2023-503290-38-00 4 2023-09-05 Bronchiectasis
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• Phase 2b study of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus (RSV) who are at high risk of progression … Recruiting
  2025-523156-31-00 4 2026-03-17 Respiratory Syncytial Virus
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting
  2024-519345-30-00 5 2025-11-12 IgA nephropathy
• Efepoetin alfa for treatment of anemia in chronic kidney disease on dialysis Recruiting
  2023-503634-50-01 5 2025-07-22 Anemia in patients with chronic kidney disease on dialysis
• A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Parti … Recruiting
  2024-517991-39-00 5 2025-07-22 Asthma
• Clinical trial of molnupiravir (MK-4482) in adults who have COVID-19 and are not hospitalized, who are at high risk for serious illness from … Recruiting
  2023-507227-36-00 5 2025-02-21 SARS-CoV-2 (COVID-19) infection
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• A Phase 3 Study to Assess the Safety and Immunogenicity of High-dose Influenza Vaccine in Adults ≥ 60 years of Age Ended recruitment
  2024-519743-15-00 5 2025-10-20 Influenza immunisation
• Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended recruitment
  2025-520488-42-00 4 2025-09-17 Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended recruitment
  2023-508085-15-00 5 2024-05-15 Chronic Obstructive Pulmonary Disease
• A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S … Ended recruitment
  2022-501622-37-00 5 2024-01-16 Multiple Sclerosis

Showing 1–24 of 40 trials